On January 28, 2016 the Food and Drug Administration (FDA) approved eribulin mesylate for some patients with liposarcoma. The approval is for patients whose cancers are advanced (metastatic) or cannot be removed by surgery (unresectable) and are no longer responding to anthracycline-based chemotherapy.
“The approval offers a therapeutic option for a disease with minimal treatment options,” said Chris Heery, M.D. Read more here.
No comments:
Post a Comment